ProSpare improves anorectal dosimetry during postoperative prostate radiotherapy in the randomized POPS trial

ProSpare reduced anorectal dose and showed numerically lower grade ≥1 bowel symptoms, with its primary two-year outcome still pending.

KEY POINTS

  • The POPS randomized phase II trial (NCT02978014) evaluated the self-inserted ProSpare rectal obturator during postoperative prostate bed radiotherapy across 10 UK centers. Of 162 randomized patients, 158 received at least one fraction, including 77 assigned to ProSpare and 81 to standard care.
  • ProSpare was inserted before simulation and each RT fraction, with embedded radiopaque markers supporting daily CBCT localization. The intervention allowed a 5-mm posterior PTV margin, compared with a median 10-mm posterior margin in the control arm; protocol regimens included 66 Gy in 33 fractions and 55 Gy in 20 fractions, with pelvic nodal RT permitted.
  • At 18 weeks, RTOG grade ≥1 GI toxicity occurred in 22/70 ProSpare patients (31.4%) versus 30/76 controls (39.4%). Corresponding GU toxicity occurred in 20/70 (28.6%) versus 28/76 (36.8%), showing numerically lower mild toxicity in the intervention arm, although this prespecified early analysis was descriptive rather than a superiority test.
  • Clinically more significant toxicity remained low and similar. At 18 weeks, grade 2 GI toxicity was 4.3% versus 4.0% and grade 2 GU toxicity 4.3% versus 2.6% with ProSpare and standard care, respectively; no RTOG grade ≥3 toxicity was present at that assessment, although one CTCAE grade 3 urinary incontinence event occurred in the ProSpare arm.
  • In the dosimetric comparison of 122 patients (61 per arm), ProSpare consistently reduced anorectal dose-volume exposure. Median relative reductions across the assessed dose-volume parameters ranged from 2.7% to 44.6% for rectum and 39.8% to 54.5% for anal canal, particularly at higher dose levels.
  • Device acceptance was high: 50/51 respondents (98%) considered ProSpare tolerable, 49/51 (96.1%) would recommend it to reduce treatment side effects, and 82.8% described insertion as very or quite easy after familiarization. No serious device-related adverse events were reported, and all patients receiving ProSpare completed treatment using the device.
  • Patient-reported bowel, urinary, sexual and general quality-of-life scores showed no meaningful between-arm difference at 18 weeks. The trial's primary endpoint, patient-reported EPIC bowel function and bother at two years, remains pending, so it is not yet established whether the improved anorectal dosimetry translates into a clinically important long-term benefit.

CLINICAL TAKEAWAY

ProSpare offers a technically practical method to improve anorectal sparing and support reduced posterior margins during prostate bed radiotherapy, with favorable patient tolerability. However, the early toxicity differences are modest and descriptive, while the awaited two-year EPIC outcome is essential to determine whether this strategy offers meaningful clinical benefit.

SOURCE

Frontiers in Oncology

Browse more research Suggest a correction